Worldwide, approximately 240 million people live with CHB and 600,000 die each year from HBV-associated liver disease and cancer. The hepatitis B program is CaroGen's lead program and has completed initial proof-of-concept testing in animals which was published in August 2015 in the Journal of Virology. The HBV program has selected a clinical candidate capable of stimulating the immune system to multiple HBV target antigens.
It is the second leading cause of cancer-related deaths in the United States. CRC was estimated to have caused over 49,000 deaths in 2016. CaroGen has embarked on a collaborative effort on CRC with prominent scientists from UConn Health. Proteins have been selected for VLV-based delivery and are undergoing lead optimization.
It is the 5th most common cause of cancer deaths for women in the US. In 2015, there were ~161,000 deaths worldwide with ~14,000 in the United States. In collaboration with Yale Medical School, CaroGen has begun investigating the utility of our VLV-based platform in the treatment of chemotherapy-resistant and recurrent ovarian cancer.